جست‌وجوی استاد و پژوهشگر

• Neuroblastoma
• Medulloblastoma
• Childhood Cancer
• +۵ مورد دیگر

Marie Arsenian Henriksson is a Professor and Academic Vice President at Karolinska Institutet, leading the "Neural differentiation as a strategy for neuroblastoma treatment" research group within the Department of Microbiology, Tumor and Cell Biology. Her work focuses on neuroblastoma, the most common extra-cranial solid tumor in children that causes the highest number of cancer-related deaths in infants, as well as medulloblastoma tumors. Her research primarily investigates the role of the MYCN oncogene, which is amplified in high-risk neuroblastoma patients and strongly associated with poor survival and an undifferentiated tumor phenotype. A key discovery from her group demonstrated that the MYCN-regulated miR-17~92 cluster targets multiple nuclear hormone receptors, with the glucocorticoid receptor (GR) emerging as particularly significant. They found that GR is a direct target of this miRNA cluster, is the most significantly downregulated nuclear hormone receptor in MYCN-amplified neuroblastoma, and shows high prognostic value for patient outcomes. Her research has revealed that low GR expression correlates with an undifferentiated phenotype and decreased patient survival. Importantly, her team showed that MYCN inhibition and subsequent reactivation of GR signaling promotes neural differentiation and reduces tumor burden. This work provides a potential differentiation-based therapeutic approach for treating neuroblastoma patients. Her research group has received substantial funding from numerous sources including the Swedish Research Council, Swedish Cancer Society, Swedish Childhood Cancer Foundation, Knut and Alice Wallenberg Foundation, and other major Swedish research organizations. Knut and Alice Wallenberg Grant for over 30M SEK (2016) Featured researcher of the month at The Swedish Childhood Cancer Foundation (2015) Professor Henriksson supervises multiple PhD students and maintains collaborations with both national and international research groups. Her work aims to translate basic molecular discoveries into novel therapeutic strategies for childhood cancers, with potential applications extending to other MYC-driven cancers.

Brisamar Estébanez Gonzálezمشاهده پروفایل

مدرس ارشد

• Exercise Physiology
• Aging and Longevity
• Obesity and Metabolic Disorders
• +۴ مورد دیگر

Brisamar Estébanez González serves as a Senior Lecturer in the Biomedical Sciences Department at the Faculty of Veterinary Medicine, University of León, Spain. Her academic profile centers on molecular exercise physiology with emphasis on aging, obesity, and neurodegenerative pathologies. Her educational foundation includes a 2021 PhD from the University of León for her dissertation Study of molecular and cellular responses in healthy elderly subjects performing a resistance training program , supervised by Dr. Javier González Gallego and Dr. María José Cuevas González. Dr. Estébanez González's research program investigates the molecular crosstalk between physical activity and age-related diseases. Key focus areas include exosome-mediated communication in obesity, klotho protein dynamics in sarcopenia, and exercise-induced neuroprotection against Alzheimer's disease. Her work bridges basic science with clinical applications through biomarker discovery and mechanistic studies of cellular stress responses. Analysis of her 15 most recent publications (2022-2025) reveals consistent exploration of exercise interventions across the lifespan - from pediatric obesity to geriatric health. Dominant themes include sarcopenic obesity pathophysiology (32% of articles), Alzheimer's disease mechanisms (20%), and exosome biomarker discovery (27%). Her methodology frequently employs molecular profiling of peripheral blood mononuclear cells and exosomal cargo analysis. She actively contributes to the BIOMEDSAL research group (Mechanisms Pathogenic and Therapeutic Approaches in Biomedicine and Health Sciences) and maintains prior affiliation with the FISBIO group (Applied Physiology to Biomedicine). Her collaborative network spans Spanish physiological sciences societies and international exercise medicine researchers.

• Microbiology
• Parasitology
• Microsporidia
• +۴ مورد دیگر

Hicham El Alaoui is a Professor in the Faculty of Biology at Clermont Auvergne University, specializing in microbiology and parasitology. His primary affiliation is with the Laboratoire Microorganismes: Génome et Environnement (LMGE), a research unit focusing on microbial genomics and environmental interactions. His research interests span several interconnected fields including Microbiology, Parasitology (particularly Microsporidia), Honeybee Health, Microalgae Applications, and Host-Parasite Interactions. Dr. El Alaoui's work demonstrates a strong focus on understanding the complex relationships between microorganisms and their hosts, with particular emphasis on honeybee pathogens and potential interventions. Analysis of his recent publications reveals a consistent research trajectory centered on microsporidian parasites (especially Nosema ceranae) and their impact on honeybee health. His work increasingly examines the interactions between pesticides and parasites, the role of gut microbiota in host defense, and potential therapeutic interventions using probiotics and natural compounds. The research spans molecular mechanisms of infection to ecological implications for honeybee populations. Dr. El Alaoui has received recognition through numerous publications in high-impact journals and has contributed significantly to understanding honeybee diseases and microsporidian biology. His collaborative work extends across multiple institutions and disciplines, reflecting the interdisciplinary nature of modern microbiological research. His research program demonstrates strong continuity from fundamental studies of microsporidian biology to applied research addressing pressing issues in apiculture and environmental health. Current work shows increasing focus on integrated approaches to honeybee health that consider multiple stressors simultaneously.

• Neurology
• Oncology
• Molecular Medicine
• +۳ مورد دیگر

Clemens Hufnagl is a researcher at the Medical University of Salzburg, specializing in neurology and oncology. His work focuses on neurovascular interventions, such as cerebral aneurysm treatment using flow diverters, and oncological research involving biomarkers and genetic polymorphisms in cancer therapy. He holds a Dr. scient. med. and MSc. Affiliations: Medical University of Salzburg Roles: Principal Investigator in multiple projects Research Interests: Combines neurosurgical techniques with molecular medicine to address neurovascular disorders and oncological challenges. Notable areas include miRNA profiling in esophageal adenocarcinoma and pharmacogenomic studies in metastatic breast cancer. Collaborations involve neurointerventional surgery and molecular genetics, with contributions to device development like the Artisse flow diverter and Bendit microcatheters. Projects: Led initiatives on cell-free DNA monitoring in head and neck cancer (2017–2018) and molecular diagnostics in metastatic tumors (2012–2013).

• Cardiovascular Science
• Ischaemic Disease
• Diabetes Complications
• +۱۰ مورد دیگر

Professor Costanza Emanueli is the British Heart Foundation Chair in Cardiovascular Science at the National Heart & Lung Institute, Faculty of Medicine, Imperial College. Her research focuses on ischaemic disease, cardiac remodelling, diabetes complications, and therapeutic angiogenesis, with a strong emphasis on molecular mechanisms underlying cardiovascular pathologies. She leads a team actively involved in translational research, collaborating locally and internationally. Key affiliations include the British Heart Foundation Centre for Research Excellence, Cardiac Function, and the Centre for Advanced Therapeutics. Research interests span non-coding RNAs (including miRNAs, lncRNAs, and circRNAs), extracellular vesicles, RNA modifications, and their roles in cardiovascular repair and disease progression. Her work integrates bioengineering, bioinformatics, and nanomedicine to develop novel diagnostic and therapeutic approaches. Recent studies emphasize machine learning applications for predicting disease outcomes and biomarker discovery, particularly in the context of COVID-19 and diabetes. Publications highlight advancements in RNA-based therapies, extracellular vesicle-mediated communication, and the regulatory roles of epigenetic modifications in cardiovascular systems. Her research also addresses translational challenges in regenerative medicine, including bioengineered devices for muscle regeneration. Collaborations with industry and academic partners drive innovation in cardiovascular care. Educational contributions include supervising master’s and PhD students, with a commitment to fostering early-career researchers through EDI initiatives. She advocates for interdisciplinary research and knowledge dissemination to bridge scientific and societal needs.

• Biliary Tract Cancer Research
• Ferroptosis
• Drug Conjugates
• +۳ مورد دیگر

Christian Reinhard Mayr is an Associate Professor and Privatdozent at the University of Salzburg, affiliated with the University Institute of Physiology and Pathophysiology and the Salzburg University Clinic for Internal Medicine 1. His research focuses on molecular mechanisms of biliary tract cancers, ferroptosis modulation, and drug development for gastrointestinal malignancies. He holds dual Master's degrees in Genetics and TREAT (Translational Research), and a Doctorate in Natural Sciences (Dr.rer.nat.). Education: Doctorate in Genetics, University of Salzburg (2015) Master's in Genetics, University of Salzburg (2012) Additional MSc in TREAT (Translational Research) Research interests include: Ferroptosis as therapeutic target in chondrocytes and cancer cells Development of drug conjugates for biliary tract cancers Preclinical models for cholangiocarcinoma drug screening Epigenetic therapy resistance mechanisms in lymphomas Biomarker discovery using multi-omics approaches His publications highlight contributions to cannabinoid-based ferroptosis modulation, drug conjugate pharmacology, and HDAC inhibitor mechanisms. Recent projects include investigating EZH1 as a therapeutic target and evaluating ouabain's anticancer potential. He has supervised multiple theses including studies on novel biliary tract cancer therapies, cardiovascular effects of aspirin, and psychocardiology. Active in teaching, he contributes to human medicine courses on respiratory systems and ECG analysis. Notable awards include the Christian Doppler Prize (2019) and scholarships from the Salzburg Science Foundation during his doctoral and master's studies.

Yuben Moodleyمشاهده پروفایل

استاد

• Idiopathic Pulmonary Fibrosis
• Lung fibrosis
• Interstitial Lung Disease
• +۵ مورد دیگر

Professor Yuben Moodley is a distinguished academic and researcher at The University of Western Australia Medical School, where he serves in the Department of Internal Medicine. He is an active consultant Respiratory Physician at Fiona Stanley Hospital and holds leadership positions including Deputy Director of the Institute of Respiratory Health. Professor Moodley is a world-renowned expert in pulmonary fibrosis and interstitial lung diseases. His research focuses on cellular therapy for lung disease, lung fibrosis, and regenerative medicine. He has conducted seminal studies including the first-ever research on signal transduction through the interleukin-6 receptor in Idiopathic Pulmonary Fibrosis (IPF), and pioneering work using stem cells from human umbilical cord and placental amnion cells to treat animal models of lung diseases. His current research investigates circulating monocytes in IPF progression, biomarker levels in patients on antifibrotics, miRNA profiling in extracellular vesicles, and spatial transcriptomics of early lung injury. Professor Moodley serves as Senior Editor for Respirology, a major journal in the field with an impact factor of 6.4. He is actively involved in developing clinical guidelines as a member of writing teams for Thoracic Society of Australia New Zealand Australasian guideline documents on interstitial lung diseases. He also serves on the inaugural national steering committee of the Australian Lung Foundation. Chief Investigator on NHMRC Centre of Research Excellence in Pulmonary Fibrosis (2023-2028) Lead coordinator for Internal Medicine in Medicine Year 3 (MD3) Deputy Director of the Institute of Respiratory Health His research has led to clinical trials for treating premature babies with bronchopulmonary dysplasia in Melbourne and has established connections between lung cancer RNA and progressive IPF. He has secured substantial research funding from NHMRC, Department of Health (Western Australia), Pfizer, and Royal Perth Hospital Medical Research Foundation.

Wenyi Guمشاهده پروفایل

پژوهشگر ارشد

• RNA interference (RNAi) based gene therapy
• Cancer therapy
• Oncogenes
• +۸ مورد دیگر

Dr. Wenyi Gu is a Research Fellow at the Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland. He holds a PhD in Biochemistry & Molecular Biology from ANU and has expertise in RNA interference (RNAi)-based therapies, cancer stem cell research, and nanotechnology-driven drug delivery. His work focuses on developing RNAi-based treatments for cancers and viral diseases, with a particular emphasis on nanoparticle delivery systems and cancer immunotherapy. Dr. Gu’s research highlights include discovering RNAi-induced immune responses against tumor antigens, leading to PNAS publications and patents licensed by Alnylam Pharmaceuticals. He has explored RNAi’s effects on cancer stem cells and pioneered virus-mimicking nanoparticles for enhanced cellular delivery. He has supervised over 20 PhD candidates in nanomedicine and cancer therapy, with ongoing projects targeting cancer stem cells and KSHV treatments. His awards include the Peter Doherty Fellowship (2006-2009) and an NHMRC Travelling Award for Harvard training (2008). His recent work includes bone-targeted nanodrugs, silk-based biomedical adhesives, and anti-KSHV therapies using miRNA-nanocarriers. Dr. Gu collaborates widely, addressing translational challenges in nanomedicine, immunotherapy, and targeted drug delivery.

Joseph M. Lunaمشاهده پروفایل

استادیار

• RNA Biology
• Molecular Virology
• Host-Pathogen Interactions
• +۴ مورد دیگر

Joseph M. Luna, PhD is an Assistant Professor in the Department of Biochemistry at Case Western Reserve University's School of Medicine. He leads the Luna Lab, which focuses on RNA-binding proteins (RBPs) in viral infections and cellular stress responses. His work uses positive-sense RNA viruses as models to study viral replication, innate immunity, and host-pathogen interactions. Member of the Center for RNA Science and Therapeutics Member of the Cancer Genomics and Epigenomics Program at Case Comprehensive Cancer Center Director of the Advanced RNA Profiling Core PhD from The Rockefeller University (2015) Postdoctoral training at The Rockefeller University Research interests include: - Subcellular RBP:RNA interaction mapping using novel spatial CLIP techniques - Dynamics of RBPs during viral infections (HCV/SARS-CoV-2) - RBP networks in innate immunity - Development of advanced RNA-profiling methods Recent work emphasizes: - Spatial resolution of RNA interactions in viral replication organelles - CRISPR-based screening for host factors in coronavirus infections - Systems-level modeling of RBP activities Key achievements include: - Co-developed SARS-CoV-2 replicon systems enabling antiviral research - Identified miR-122 sequestration mechanisms in hepatitis C infection - Trained students from underrepresented groups in biomedical research Labs/Teams: - Advanced RNA Profiling Core facility director - Collaborations with virology, immunology, and systems biology groups

Vincent Chenمشاهده پروفایل

استادیار

• Proteomics
• Cancer Biology
• Mass Spectrometry
• +۳ مورد دیگر

Dr. Vincent Chen is an Assistant Professor in the Department of Chemistry at Brandon University and Director of the Brandon University Proteomics Centre. His research focuses on proteomics, mass spectrometry, and their applications in understanding cancer biology, protein interactions, and drug development. He holds a BSc and PhD in Chemistry. Key research areas include the molecular mechanisms of cancer resistance (e.g., glioblastoma and prostate cancer), proteomic profiling of secretomes and interactomes, and the development of novel therapeutic strategies targeting enzymes like IDH1 and MMP3. His work integrates advanced mass spectrometry techniques with systems biology approaches. Dr. Chen’s lab (www.chenlab.ca) has published extensively on topics such as Temozolomide resistance in glioma cells, Cx43-mediated signaling pathways, and the role of ubiquitin ligases in protein regulation. Recent studies explore synergistic mechanisms of cancer metastasis and drug resistance using multidisciplinary proteomic methods. No scientific awards were explicitly mentioned in the provided texts. His advising and grant activities are not detailed here, but his research aligns with significant contributions to clinical proteomics and cancer research. He leads the Brandon University Proteomics Centre, focusing on translational research at the interface of chemistry and oncology.

• Stem Cell Biology
• Developmental Biology
• Muscle Regeneration
• +۶ مورد دیگر

Maurilio Sampaolesi is a full professor at the Faculty of Medicine , KU Leuven, affiliated with the Department of Development and Regeneration and leading the Stem Cell and Developmental Biology unit. His work bridges basic research and translational applications in regenerative medicine. Research focuses on stem cell biology , muscle regeneration , and cardiac therapy . Key projects include exploring extracellular vesicles for muscle repair, iPSC-derived models for cystinosis, and paracrine therapy for heart disease. His studies span cancer biology (e.g., rhabdomyosarcoma) and aging-related disorders . Recent publications and projects highlight expertise in gene circuits , secretome engineering , and 3D spatial omics . He contributes to translational grants as promotor or co-promotor, including AmnioSMART (ERA4Health-funded) and cystinosis research initiatives. As a member of academic councils and committees, he drives research strategy in developmental biology and regenerative medicine . His teaching includes courses like Advances in Stem Cell Biology (E0E36A) and Hot Topics in Stem Cell Biology (E0E37A).

Patrick Leaveyمشاهده پروفایل

استاد

• Pediatric Oncology
• Translational Research
• Clinical Trials
• +۵ مورد دیگر

Patrick Leavey, M.D. is a Professor of Pediatrics at UT Southwestern Medical Center and a Pediatric Oncologist at Children’s Health, Children’s Medical Center Dallas and Plano. He holds leadership roles including Associate Vice Chair for Research Operations in the Department of Pediatrics, Associate Director for Clinical Research at the Harold C. Simmons Comprehensive Cancer Center, and Immediate Past President of the Active Medical/Dental Staff at Children's Medical Center Dallas. Former President of the American Society of Pediatric Hematology/Oncology (ASPHO) Long-standing member of the Children’s Oncology Group (COG) Bone Sarcoma Steering Committee until 2023 Co-chair for COG study AOST2031 and Principal Investigator for grants from CPRIT, Team Connor Foundation, and American Society of Hematology Research Interests include clinical and translational trials in pediatric sarcomas (osteosarcoma, Ewing sarcoma, rhabdomyosarcoma), with a focus on biomarker development, machine learning applications in tumor classification, and sickle cell disease clinical trials. His work also addresses communication training for pediatric oncology fellows and treatment intensification protocols. Key projects: Machine learning for viable tumor identification in osteosarcoma Development of whole slide imaging tools for pediatric rhabdomyosarcoma Leadership in establishing the North Texas Sickle Cell Disease Clinical Trial Unit Publications (2016-2022) highlight advancements in sarcoma prognosis, tumor necrosis assessment, circulating tumor DNA analysis, and metabolic profiling. Recent studies emphasize precision medicine, molecular biomarkers, and AI integration in pathology. Grants & Collaborations include CPRIT funding for imaging studies, Team Connor Foundation awards for machine learning in osteosarcoma, and ASH grants for sickle cell disease clinical trials.

Tamang Tej Manمشاهده پروفایل

استادیار

• Plant tissue culture
• Transformation
• Genetic engineering
• +۷ مورد دیگر

Tamang Tej Man, Ph.D. is an Assistant Professor in the Environmental Horticulture department at York College of Pennsylvania's Kinsley School of Engineering, Sciences and Technology . He holds a Ph.D. and completed postdoctoral research at Kansas State University, focusing on genetic engineering and stress physiology of crops. Education: Postdoctoral Fellow, Kansas State University Ph.D. in Horticulture, Kansas State University Research Interests center on abiotic stress tolerance in maize and rice, genetic engineering for stress adaptation, and plant tissue culture for crop improvement. His work investigates molecular mechanisms of heat, drought, and salinity resistance through transgenic and gene editing approaches. Publication Trends show a focus on genetic modification of cereal crops , particularly maize and rice, for enhanced resistance to biotic (e.g., bacterial wilt, blast disease) and abiotic stresses. Techniques include CRISPR/Cas9 , transcriptomic profiling , and redox engineering . Collaborative studies explore effector internalization and artificial transcription factor systems .

• MicroRNA in Cancer
• Triple-Negative Breast Cancer
• Biomarker Discovery
• +۳ مورد دیگر

Ali Afsari, MD is an Assistant Professor in the Department of Pathology at the University of California, Irvine (UCI) School of Medicine . His research focuses on the molecular mechanisms underlying cancer prognosis, particularly in ethnic populations. He has conducted significant studies on microRNA (miRNA) expression patterns in African-American patients with triple-negative breast cancer (TNBC), identifying miRNA panels associated with tumor aggressiveness and survival outcomes. His work employs advanced bioinformatics tools like KMplotter and miRTargetLink to map miRNA/mRNA networks, revealing critical cancer-related genes such as AKT1 , BCL2 , and PTEN . The research emphasizes proteoglycan and glycan pathways as key contributors to TNBC progression in African-American populations. Dr. Afsari's study was supported by grants from the National Institutes of Health (NIH) (P30 CA016058, P30 CA051008, U54 MD007597). His findings highlight the role of miRNA deregulation in conferring aggressive phenotypes to TNBC cells, offering potential biomarkers for early detection and therapeutic targeting.

Marieke Verleihمشاهده پروفایل

پژوهشگر

• Fish Genetics
• Aquaculture
• Molecular Biology
• +۷ مورد دیگر

Dr. Marieke Verleih is a scientist at the Research Institute for Farm Animal Biology (FBN) in Dummerstorf, Germany, where she has been a key member of the Fish Genetics Group since 2012. She currently holds a permanent scientific position, having previously served as a postdoctoral researcher. Her work is centered on improving fish welfare and productivity in aquaculture through genomic and molecular approaches. PhD in Molecular Biology (2012) Diploma in Biology from Philipps University of Marburg and the University of Rostock (2001–2007) Her research focuses on identifying early genomic and physiological indicators of stress and suboptimal housing conditions in farmed fish. She investigates the genetic basis of stress tolerance, immune function, and developmental processes in species such as rainbow trout and pikeperch. Her work integrates transcriptomics, genomics, and functional analyses to uncover mechanisms underlying adaptation and resilience. The trends in her recent publications highlight a strong emphasis on stress physiology, immune responses, and genomic characterization in aquaculture species. Her studies often explore the interaction between environmental stressors (temperature, hypoxia, stocking density) and molecular responses, contributing to the development of sustainable and welfare-oriented fish farming practices. Active scientific contributions to high-impact journals in aquaculture and molecular biology Extensive collaboration with leading researchers in fish genomics and immunology Dr. Verleih has not publicly listed any PhD or Master’s students, but her leadership in numerous collaborative research projects suggests a mentoring role within the Fish Genetics Group. She has been involved in multiple studies funded through institutional and national research programs, though specific grants are not detailed in the provided text. Her work supports the broader mission of FBN to advance sustainable animal production through biological research. She conducts her research within the Fish Genetics Group at FBN, a multidisciplinary team focused on the genetic improvement and welfare of farmed fish species. The group employs cutting-edge molecular and bioinformatic tools to address challenges in modern aquaculture.